Bone Turnover Markers in Patients With Nonalcoholic Fatty Liver Disease and/or Type 2 Diabetes During Oral Glucose and Isoglycemic Intravenous Glucose

Autor: Lise Lotte Gluud, Tina Vilsbøll, Niklas Rye Jørgensen, Henrik Maagensen, Anders Ellekær Junker, Filip K. Knop
Rok vydání: 2018
Předmět:
0301 basic medicine
Blood Glucose
Male
endocrine system diseases
Endocrinology
Diabetes and Metabolism

Clinical Biochemistry
Administration
Oral

Type 2 diabetes
Biochemistry
Bone remodeling
Cohort Studies
Liver disease
0302 clinical medicine
Endocrinology
Non-alcoholic Fatty Liver Disease
Nonalcoholic fatty liver disease
Glucose tolerance test
biology
medicine.diagnostic_test
Middle Aged
Bone Remodeling/physiology
Osteocalcin
Administration
Intravenous

Female
Bone Remodeling
Diabetes Mellitus
Type 2/blood

Adult
medicine.medical_specialty
030209 endocrinology & metabolism
Context (language use)
03 medical and health sciences
Blood Glucose/drug effects
Internal medicine
Diabetes mellitus
medicine
Humans
Aged
business.industry
Biochemistry (medical)
nutritional and metabolic diseases
Glucose Tolerance Test
medicine.disease
Glucose/administration & dosage
030104 developmental biology
Cross-Sectional Studies
Glucose
Diabetes Mellitus
Type 2

Non-alcoholic Fatty Liver Disease/blood
biology.protein
business
Biomarkers/blood
Biomarkers
Zdroj: BASE-Bielefeld Academic Search Engine
Maagensen, H, Junker, A E, Jørgensen, N R, Gluud, L L, Knop, F K & Vilsbøll, T 2018, ' Bone Turnover Markers in Patients with Nonalcoholic Fatty Liver Disease and/or Type 2 Diabetes during Oral Glucose and Isoglycemic Intravenous Glucose ', Journal of Clinical Endocrinology and Metabolism, vol. 103, no. 5, pp. 2042-2049 . https://doi.org/10.1210/jc.2018-00176
ISSN: 1945-7197
DOI: 10.1210/jc.2018-00176
Popis: Context: Nonalcoholic fatty liver disease (NAFLD) is associated with type 2 diabetes (T2D) and vice versa, and both conditions are associated with an increased risk of fractures and altered bone turnover. Although patients with NAFLD typically suffer from decreased bone mineral density (BMD), T2D is associated with normal to high BMD. The pathophysiology is uncertain but may involve the gut-bone axis. Objective: We investigated the influence of the gut on glucose-induced changes in plasma bone turnover markers in healthy controls and patients with T2D and/or biopsy-verified NAFLD. Design: Cross-sectional cohort study. Patients: Patients with NAFLD with normal glucose tolerance, patients with NAFLD and T2D, patients with T2D without liver disease, and healthy controls. Interventions: Four-hour 50-g oral glucose tolerance test (OGTT) and an isoglycemic intravenous glucose infusion (IIGI). Main Outcome Measures: Collagen type 1 C-telopeptide (CTX), osteocalcin, procollagen type 1 N-terminal propeptide (P1NP), and parathyroid hormone. Results: Plasma glucose levels achieved during OGTTs were successfully matched on corresponding IIGI days. Patients with NAFLD and T2D exhibited similar CTX suppression during the two glucose challenges (P = 0.46) and pronounced suppression of P1NP during IIGI compared with OGTT. Conversely, remaining groups showed greater (P < 0.05) CTX suppression during OGTT and similar suppression of bone formation markers during IIGI and OGTT. Conclusions: OGTT-induced CTX suppression seems to be impaired in patients with NAFLD and T2D, but preserved in patients with either NAFLD or T2D, suggesting that coexistence of T2D and NAFLD may affect gut-bone axis.
Databáze: OpenAIRE